Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Differences in biofilm formation and aggregative adherence between beta-lactam susceptible and beta-lactamases producing P. mirabilis clinical isolates.

Nucleo E, Fugazza G, Migliavacca R, Spalla M, Comelli M, Pagani L, Debiaggi M.

New Microbiol. 2010 Jan;33(1):37-45.

2.

Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.

Luzzaro F, Perilli M, Amicosante G, Lombardi G, Belloni R, Zollo A, Bianchi C, Toniolo A.

Int J Antimicrob Agents. 2001 Feb;17(2):131-5.

PMID:
11165117
3.

Molecular epidemiology of ESbetaL producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy.

Migliavacca R, Migliavacca A, Nucleo E, Ciaponi A, Spalla M, De Luca C, Pagani L.

New Microbiol. 2007 Jul;30(3):362-6.

4.

Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.

Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, Huang IW, Tan MC, Lauderdale TL; TSAR Hospitals..

BMC Infect Dis. 2014 Sep 5;14:486. doi: 10.1186/1471-2334-14-486.

5.

Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Pagani L, Migliavacca R, Pallecchi L, Matti C, Giacobone E, Amicosante G, Romero E, Rossolini GM.

J Clin Microbiol. 2002 Apr;40(4):1549-52.

6.

Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.

Kanayama A, Iyoda T, Matsuzaki K, Saika T, Ikeda F, Ishii Y, Yamaguchi K, Kobayashi I.

Int J Antimicrob Agents. 2010 Oct;36(4):340-2. doi: 10.1016/j.ijantimicag.2010.06.002.

PMID:
20609568
7.

Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.

Aragón LM, Mirelis B, Miró E, Mata C, Gómez L, Rivera A, Coll P, Navarro F.

J Antimicrob Chemother. 2008 May;61(5):1029-32. doi: 10.1093/jac/dkn056.

8.

[Characteristic of resistance to beta-lactam antibiotics of nosocomial strains of Proteus mirabilis].

Ivanov DV.

Zh Mikrobiol Epidemiol Immunobiol. 2008 Nov-Dec;(6):75-8. Russian.

PMID:
19189465
9.

Acquired AmpC type beta-lactamases: an emerging problem in Italian long-term care and rehabilitation facilities.

Migliavacca R, Nucleo E, D'Andrea MM, Spalla M, Giani T, Pagani L.

New Microbiol. 2007 Jul;30(3):295-8.

10.

High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia.

Tonkic M, Mohar B, Sisko-Kraljević K, Mesko-Meglic K, Goić-Barisić I, Novak A, Kovacić A, Punda-Polić V.

J Med Microbiol. 2010 Oct;59(Pt 10):1185-90. doi: 10.1099/jmm.0.016964-0.

PMID:
20558587
11.

[The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].

Kwiecińska-Piróg J, Bogiel T, Gospodarek E.

Przegl Epidemiol. 2010;64(3):395-8. Polish.

PMID:
20976952
12.

Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.

Luzzaro F, Brigante G, D'Andrea MM, Pini B, Giani T, Mantengoli E, Rossolini GM, Toniolo A.

Int J Antimicrob Agents. 2009 Apr;33(4):328-33. doi: 10.1016/j.ijantimicag.2008.09.007.

PMID:
19095415
13.

The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.

Yong D, Lim YS, Roh KH, Choi YS, Park DY, Yum JH, Kim JM, Lee K, Chong Y.

Diagn Microbiol Infect Dis. 2006 Mar;54(3):237-9.

PMID:
16427241
14.

Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal.

Féria C, Ferreira E, Correia JD, Gonçalves J, Caniça M.

J Antimicrob Chemother. 2002 Jan;49(1):77-85.

15.

Prevalence of extended spectrum beta lactamase and AmpC beta lactamase producers among Escherichia coli isolates in a tertiary care hospital in Jaipur.

Sinha P, Sharma R, Rishi S, Sharma R, Sood S, Pathak D.

Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):367-9.

16.

Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase.

Tsakris A, Ikonomidis A, Poulou A, Spanakis N, Pournaras S, Markou F.

J Antimicrob Chemother. 2007 Jul;60(1):136-9.

17.

Ulcer infection by ESbetaL-producing Proteus mirabilis: a case report.

Savini V, Catavitello C, Talia M, Di Berardino F, Manna A, Balbinot A, Febbo F, Carlino D, Fioritoni F, Di Bonaventura G, D'Antonio D.

Int J Low Extrem Wounds. 2008 Jun;7(2):99-101. doi: 10.1177/1534734608316107.

PMID:
18483010
18.

Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.

Nakano R, Nakano A, Abe M, Inoue M, Okamoto R.

J Med Microbiol. 2012 Dec;61(Pt 12):1727-35. doi: 10.1099/jmm.0.049726-0.

PMID:
22935848
19.

Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.

Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A.

Antimicrob Agents Chemother. 2005 Jul;49(7):2598-605.

20.

[Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].

Treviño M, Navarro D, Barbeito G, Areses P, García-Riestra C, Regueiro BJ.

Rev Esp Quimioter. 2012 Jun;25(2):122-8. Spanish.

Items per page

Supplemental Content

Support Center